Abstract
Purpose
S-1 is a novel oral fluoropyrimidine comprised of FT and two modulators, gimeracil (CDHP) and oteracil potassium (Oxo). This study investigated the food effects on the pharmacokinetics (PK) of Oxo, other components of S-1, and their metabolites at different gastric pH adjusted by proton pump inhibitor (PPI).
Methods
Patients with and without PPI were treated with S-1 at 30 mg/m2 twice daily orally on days 1–7 under either fed or fasting condition, and then were crossed over to fasting/fed conditions on days 15–21 with washout on days 8–14 and 22–28.
Results
The study enrolled 55 patients including 27 PK-evaluable patients. For the single-dose and multiple-dose pharmacokinetics, the administration of S-1 under fed conditions resulted in decreased exposure to Oxo relative to fasting administration. There was a marginal decrease in exposure to CDHP and 5-FU under fed versus fasting conditions, although FT exposure was not altered by food, which demonstrated lack of food effect. PPI administration together with S-1 did not significantly change its bioavailability.
Conclusions
Oxo exposure was reduced under fed compared to fasting condition. To increase the bioavailability of S-1, the administration of S-1 under fasting condition was more effective in the western countries.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Shirasaka T, Shimamato Y, Ohshimo H et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumour selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548–557
Anttila MI, Sotaniemi EA, Kairaluoma MI et al (1983) Pharmacokinetics of Ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol 10:150–153
Diasio RB, Harris BE (1989) Clinical pharmacology of 5- fluorouracil. Clin Pharmacokinet 16:215–237
Iyer L, Ratain MJ (1999) 5-Fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Investig 17:494–506
Tatsumi K, Fukushima M, Shirasaka T et al (1987) Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78(7):748–755
Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53(17):4004–4009
Takechi T, Nakano K, Uchida J et al (1997) Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 39(3):205–211
Shirasaka T, Shimamoto Y, Kato T et al (1998) Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil [in Japanese]. Jpn J Cancer Chemother 25:371–384
Kato T, Shimamoto Y, Uchida J (2001) Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5- fluorouracil. Anticancer Res 21:1705–1712
The effect of food on the pharmacokinetics of S-1 after single administration in human plasma of patients with solid tumors (2001) Clinical Study Report (Taiho Pharmaceutical Co., Ltd.)
Savarino V, Mela GS, Zentilin G et al (1998) Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. Aliment Pharmacol Ther 12:1241–1247
Tutuian R, Katz PO, Bochenek W et al (2002) Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers. Aliment Pharmacol Ther 16:829–836
Sakuramoto S, Sasako M, Yamaguchi T, ACTS-GC Group et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18):1810–1820
Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215–221
Kato K, Muro K, Yasui H et al (2009) The FIRIS study; a phase III trial of 5FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as 2nd-line chemotherapy for metastatic colorectal cancer (mCRC) [FIRIS study group]. Eur J Cancer Suppl 7(2):324
Ajani JA, Rodriguez W, Bodoky G et al (2010) Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28(9):1547–1553
Yoshioka H, Okamoto I, Morita S et al (2010) Randomized phase III study of carboplatin plus S-1 compared with carboplatin plus paclitaxel as first-line chemotherapy in advanced non-small cell lung cancer (WJTOG3605). J Clin Oncol 28:7s suppl; abstr 7530
Hirata K, Horikoshi N, Aiba K et al (1999) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5(8):2000–2005
Yoshida K, Ikeda K, Yoshisue K et al. (2011) Population pharmacokinetic (PPK) analysis for 5-FU, tegafur (FT), gimeracil (CDHP), and oteracil potassium (Oxo) in the eight clinical studies of S-1 in Western patients with advanced solid tumors. J Clin Oncol 29, (suppl 4; abstr 53)
Peters GJ, Noordhuis P, Van Groeningen CJ et al (2004) The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. Clin Cancer Res 15(10):4072–4076
Reigner B, Verweij J, Dirix L et al (1998) Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 4(4):941–948
Conflict of interest
KS and CZ are employees of Taiho Pharma, USA, Inc. No other potential conflict of interest relevant to this article was reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Scheulen, M.E., Saito, K., Hilger, R.A. et al. Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors. Cancer Chemother Pharmacol 69, 753–761 (2012). https://doi.org/10.1007/s00280-011-1761-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-011-1761-2